11-Beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in Type 2 diabetes mellitus and obesity
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Glucocorticoids such as cortisol are important regulators of fuel metabolism during starvation and stress. Chronic glucocorticoid excess induces obesity with multiple features of the metabolic syndrome. OBJECTIVE: In this article, we review the importance of glucocorticoids in metabolic syndrome and the approaches that have been explored to reduce glucocorticoid action as the basis for novel therapy of Type 2 diabetes and obesity. METHOD: We focus on the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), which amplifies glucocorticoid concentrations in key metabolic tissues including liver and adipose tissue. RESULTS/CONCLUSION: Several 11beta-HSD1 inhibitors are in late preclinical or early clinical development and we review here the properties of the class leaders and their potential as the next generation of drugs with multiple benefits in metabolic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults
Calle, E. E., Thun, M. J., Petrelli, J. M., Rodriguez, C., & Heath, C. W. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910073411501 · Cited by 3,643
Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766 · cited 3×
“Drugs (2008) 17(4) 483 have normal serum glucocorticoid levels, as in human obesity [42] .”
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461 · cited 1×
“It is now recognised that both fasting and postprandial hyperglycaemia have important roles in the metabolic abnormalities found in Type 2 diabetes [127] , and targeting glucose levels usually requires a combination of drugs and/or insulin.”
11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969 · cited 1×
“In addition to its expression in liver and adipose tissue, 11 β -HSD1 is active in a number of other cells and tissues [115] .”
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801
Does central obesity reflect “Cushing's disease of the omentum”?
Bujalska, I. J., Kumar, S., & Stewart, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11222-8 · Cited by 753 · cited 1×
“11 β -HSD1 is highly expressed in the liver [31] and in adipose tissue [32] , although it is also found in a number of other tissues, including brain [33] , blood vessel wall [34] , macrophages [35] , eye [36] , bone [37] , lung [38] and ovary [39] .”
Goodpaster, B. H., Krishnaswami, S., Resnick, H., Kelley, D. E., Haggerty, C., Harris, T. B., Schwartz, A. V., Kritchevsky, S., & Newman, A. B. (2003) · Diabetes Care · doi:10.2337/diacare.26.2.372 · Cited by 619
Glucocorticoids and cardiovascular disease
Walker, B. R. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0455 · Cited by 529 · cited 1×
“There is some evidence of GR dysfunction in metabolic syndrome [27] , perhaps with a genetic basis [29] .”
Self-citationMorton, N. M., Paterson, J. M., Masuzaki, H., Holmes, M. C., Staels, B., Fievet, C., Walker, B. R., Flier, J. S., Mullins, J. J., & Seckl, J. R. (2004) · Diabetes · doi:10.2337/diabetes.53.4.931 · Cited by 512 · cited 1×
“11 β -HSD1 -/- mice also have a favourable lipid and lipoprotein profile compared to controls [61] and a metabolically favourable adipose tissue distribution, even on a C57BL6J background, which is susceptible to obesity and diabetes [62] .”
Self-citationBays, H. E., Chapman, R. H., Grandy, S., & the SHIELD Investigators’ Group (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01336.x · Cited by 510 · cited 3×
“1 Adamantyl triazoles Merck Laboratories has discovered that 3-(1-adamantyl)6,7,8,9-tetrahydro-5 H -[1,2,4] triazolo[4,3a ]azepine, named Compound 544 ( 2 ), is a potent inhibitor of 11 β -HSD1.”
Brochu, M., Tchernof, A., Dionne, I. J., Sites, C. K., Eltabbakh, G. H., Sims, E. A. H., & Poehlman, E. T. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7365 · Cited by 443 · cited 1×
“Although national health surveys estimate that more than 80% of all individuals with Type 2 diabetes are either overweight or obese [4] , not everyone with obesity is equally at risk [7] , and indeed, the majority of obese individuals do not develop diabetes [8] .”
Stewart, P. M., Boulton, A., Kumar, S., Clark, P. M. S., & Shackleton, C. H. L. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.3.5538 · Cited by 398
Polyglandular Autoimmune Syndromes: Immunogenetics and Long-Term Follow-Up
Dittmar, M., & Kahaly, G. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021845 · Cited by 367
Adrenal glands of mouse and rat do not synthesize androgens
van Weerden, W. M., Bierings, H. G., Van Steenbrugge, G. J., De Jong, F. H., & Schröder, F. H. (1992) · Life Sciences · doi:10.1016/0024-3205(92)90204-3 · Cited by 260 · cited 1×
“As rodents lack the 17 α -hydroxylase enzyme in the adrenal and are unable to synthesise C-19 steroids such as dehydroepiandrosterone [125] , this does not cause adverse effects in rats.”
Glucocorticoids and 11beta-Hydroxysteroid Dehydrogenase in Adipose Tissue
Seckl, J. R. (2004) · Recent Progress in Hormone Research · doi:10.1210/rp.59.1.359 · Cited by 239 · cited 1×
“The majority of murine cholesterol is in the form of high-density lipoprotein (HDL), whilst in humans low-density lipoprotein predominates [130] .”
Lindsay, R. S., Wake, D. J., Nair, S., Bunt, J., Livingstone, D. E. W., Permana, P. A., Tataranni, P. A., & Walker, B. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-030017 · Cited by 225
Self-citationLavery, G. G., Walker, E. A., Draper, N., Jeyasuria, P., Marcos, J., Shackleton, C. H. L., Parker, K. L., White, P. C., & Stewart, P. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512635200 · Cited by 207 · cited 1×
“Some concerns have been expressed about whether 11 β -HSD1 inhibition will always lower intracellular cortisol concentrations following the description of potential reversibility of enzyme activity in mice with hexose-6phosphate dehydrogenase (H6PDH) deficiency [123] .”
Kannisto, K., Pietiläinen, K. H., Ehrenborg, E., Rissanen, A., Kaprio, J., Hamsten, A., & Yki-Järvinen, H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0153 · Cited by 205 · cited 1×
“Similar differences have been described in obese humans, in whom there is reduced hepatic [44-46] and increased adipose [44,45,47-54] 11 β -HSD1 activity.”
Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans.
Liu, H., Bravata, D. M., Cabaccan, J., Raff, H., & Ryzen, E. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02395.x · Cited by 178
Hewitt, K. N., Walker, E. A., & Stewart, P. M. (2005) · Endocrinology · doi:10.1210/en.2005-0117 · Cited by 149
Cited by
11β-Hydroxysteroid dehydrogenases and the brain: From zero to hero, a decade of progress
Wyrwoll, C. S., Holmes, M. C., & Seckl, J. R. (2011) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2010.12.001 · Cited by 244
“of glucocorticoid-lowering therapies in metabolic syndrome and depression [109,263,295,320] suggest a role in pathogenesis and/”
Stimson, R. H., Andrew, R., McAvoy, N. C., Tripathi, D., Hayes, P. C., & Walker, B. R. (2011) · Diabetes · doi:10.2337/db10-0726 · Cited by 67
Self-citationGlucocorticoids Turn Over Slowly in Human Adipose Tissue in Vivo
Hughes, K. A., Reynolds, R. M., Andrew, R., Critchley, H. O. D., & Walker, B. R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0384 · Cited by 32
Self-citationMorgan, R. A., Beck, K. R., Nixon, M., Homer, N. Z. M., Crawford, A. A., Melchers, D., Houtman, R., Meijer, O. C., Stomby, A., Anderson, A. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10410-1 · Cited by 31
Self-citationKetoconazole enantiomer for the treatment of diabetes mellitus
Arakaki, R., & Welles, B. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903381411 · Cited by 21
Metadata
- Authors
- Hughes, K. A., Webster, S. P., & Walker, B. R.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2008-03-25
- Volume
- 17
- Issue
- 4
- Pages
- 481-496
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2064249167
- Cited by
- 102
- References
- 22
- FWCI
- 10.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.